


# PRODUCT INFORMATION



## Ralinepag

Item No. 30009

**CAS Registry No.:** 1187856-49-0  
**Formal Name:** 2-[[*trans*-4-[[[(4-chlorophenyl)phenylamino]carbonyl]oxy]methyl]cyclohexyl]methoxy]-acetic acid  
**MF:** C<sub>23</sub>H<sub>26</sub>ClNO<sub>5</sub>  
**FW:** 431.9  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Ralinepag is supplied as a solid. A stock solution may be made by dissolving the ralinepag in the solvent of choice, which should be purged with an inert gas. Ralinepag is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of ralinepag in these solvents is approximately 10 mg/ml in ethanol and DMSO and approximately 15 mg/ml in DMF.

Ralinepag is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ralinepag should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Ralinepag has a solubility of approximately 0.11 mg/ml in a 1:8 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

Ralinepag is a prostaglandin I<sub>2</sub> (PGI<sub>2</sub>) receptor (IP) agonist (K<sub>i</sub> = 3 nM).<sup>1</sup> It is selective for IP over the PGD<sub>2</sub> receptor (DP<sub>1</sub>) and the PGE<sub>2</sub> receptor subtypes EP<sub>1-4</sub> (K<sub>i</sub>s = 2,600, 9,600, 611, 143, and 678 nM, respectively, in radioligand binding assays). Ralinepag induces cAMP accumulation in CHO-K1 cells expressing human recombinant IP (EC<sub>50</sub> = 8.5 nM). *In vivo*, ralinepag (30 mg/kg) prevents increases in pulmonary arterial pressure and vessel wall thickness in a rat model of monocrotaline-induced pulmonary arterial hypertension.

### Reference

1. Tran, T.-A., Kramer, B., Shin, Y.-J., *et al.* Discovery of 2-(((1*r*,4*r*)-4-(((4-chlorophenyl)(phenyl)carbamoyl)oxy)methyl)cyclohexyl)methoxy)acetate (Ralingepag): An orally active prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. *J. Med. Chem.* **60**(3), 913-927 (2017).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 01/03/2023

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)